USPTO Patent Applications - Pharma (A61K)

Fused Amino Pyrimidine Compounds Treat Tinnitus, Hearing Loss, Meniere's

USPTO published Patent Application US20260108529A1 on April 23, 2026, filed by inventor Zhong Zhong on October 23, 2025 (Application No. 19366802), covering fused amino pyrimidine compounds for treating tinnitus, acute sensorineural hearing loss, age-related hearing loss, and Meniere's disease. The application discloses therapeutic compositions containing compounds according to Formula (I) or their pharmaceutically acceptable salts, classified under CPC codes A61K 31/5377, A61K 31/519, A61K 31/5517, A61K 45/06, and A61P 27/16.

Transnasal Testosterone Gel for Hypogonadism in Males with Allergic Rhinitis

USPTO published patent application US20260108531A1 by inventor Natalia Tkachenko on April 23, 2026, covering methods of treating hypogonadism in males via intranasal testosterone bio-adhesive gel formulations. The application discloses 4.0% and 4.5% testosterone gel compositions that remain effective when allergic rhinitis occurs or when topical nasal vasoconstrictors or decongestants are used during treatment. Filing date was March 20, 2025; application number 19085870.

Cannabinoid Nanoplatform Treats Knee Osteoarthritis

USPTO published patent application US20260108539A1, filed October 21, 2024 by Cannabis Bioscience International Holdings Inc, covering a cannabinoid-based nanoplatform composition and methods for treating knee osteoarthritis via intra-articular injection. The composition combines phytocannabinoids CBG and CBC with hyaluronic acid, type II collagen, and calcium gluconate, targeting joint pain, stiffness, reduced mobility, inflammation, and cartilage degeneration in osteoarthritis patients. The nanoemulsification-based production process creates particles smaller than 200 nm with pre-sterilization via membrane filtration.

Pharmaceutical Composition for Preventing Heart Disease and Pulmonary Hypertension in Animals

CARESIDE CO., LTD. has published patent application US20260108532A1, filed September 6, 2023, covering a pharmaceutical composition for preventing and treating heart disease and pulmonary hypertension in animals. The composition includes the active pharmaceutical ingredients pimobendan, enalapril, torsemide, and spironolactone. The application was published on April 23, 2026, under CPC classifications A61K and A61P relating to pharmaceutical preparations for cardiovascular conditions.

Bradykinin Receptor Antagonist Compounds for Pain Relief

The USPTO published patent application US20260108535A1 on April 23, 2026, covering bradykinin receptor antagonist compounds for therapeutic use. The application (No. 19423236, filed December 17, 2025) specifies pharmaceutical compositions for treatment of urinary bladder pain and symptomatic relief of pain, burning, urgency, and frequency arising from lower urinary tract mucosa irritation caused by infection, trauma, surgery, endoscopic procedures, or catheter passage. The named inventors include Pathik Subhashchandra Brahmkshatriya, Vishal Bharatbhai Unadkat, Vishalgiri Gunvantgiri Goswami, Heta Nishil Pandya, and Sandip Pareshbhai Mehta.

Liposomal BCL Inhibitors for Hyperproliferative Disorders

USPTO published patent application US20260108534A1 on April 23, 2026, filed September 30, 2025 under Application No. 19345495. The application covers liposomes containing B-cell lymphoma (Bcl) protein inhibitors, pharmaceutical compositions thereof, and methods of using such formulations for treating hyperproliferative disorders. Inventors: Paul Tardi, Leon Wan, Shyam Madhusudan Garg, Jun Gao, and Philippe Legros.

Shingles Treatment Cannabinoid Nanoplatform CBD CBG

Cannabis Bioscience International Holdings Inc published USPTO patent application US20260108537A1 on April 23, 2026 (filed October 18, 2024, Application No. 18920359), disclosing a cannabinoid-based nanoplatform for treating shingles using CBD and CBG in oral capsule and topical cream formulations with particles smaller than 200 nm. The invention targets acute shingles symptoms and postherpetic neuralgia with systemic anti-inflammatory, antiviral, and neuroprotective effects alongside localized pain and itch relief. This is a patent publication event creating no compliance obligations.

Cannabis Bioscience Nanoparticle Breast Cancer Treatment

Cannabis Bioscience International Holdings Inc has filed patent application US20260108536A1 for a cannabinoid-based nanoplatform composition targeting breast cancer treatment. The composition incorporates phytocannabinoids (THC, CBD, CBG, CBC) into nanoparticles smaller than 200 nm using nano-emulsification techniques for enhanced bioavailability and controlled release. The treatment targets ER+, PR+, HER2-positive, and triple-negative breast cancers at stages I and II by inhibiting VEGF pathways and inducing apoptosis.

Silver Nanoparticle Treatment for Carious Lesions, 3-5 Weeks

The USPTO published patent application US20260096959A1 filed by R.M CREIGHTON DENTAL PTY LTD for a method of treating carious lesions using silver nanoparticles. The treatment involves applying a first dental solution containing a silver salt followed by a second dental solution containing a reducing agent within less than 10 minutes. The lesion consolidates over 3-5 weeks to form a matte black crust containing nanoparticles. Invented by Graham G. Craig.

Anhydrous Powder Hair Lightening Suspension

USPTO published patent application US20260096960A1 by inventor David Erlingheuser for an anhydrous powder hair lightening suspension composition on April 9, 2026. The composition comprises 5-60% non-volatile oil, 3-30% petrolatum, 0.05-5% fumed silica, 1-70% persulfate salt, and 0% microplastics. This publication establishes a priority date and provides public notice of the pending patent claims.

Novel Formulations and Vehicles for DAPTZ Compounds Including Methylene Blue

USPTO published patent application US20260097043A1 assigned to WisTa Laboratories Ltd., covering novel oral pharmaceutical formulations of diaminophenothiazine (DAPTZ) compounds such as methylene blue. The application discloses gastro-retentive platforms including film-coated solid tablets and buoyant self-orientating capsules with sustained-release coatings. The filing was submitted on September 20, 2023, under application number 19113777.

Cholesterol Efflux Modulation Compositions and Methods - US20260097053A1

USPTO published patent application US20260097053A1 for compositions and methods modulating cholesterol efflux via ABCA1 for treating atherosclerosis and related diseases. Invented by Kailash Gulshan, the application claims PIP2 compositions affecting ABCA1 levels and promoting reverse cholesterol transport (RCT) to reduce cholesterol and atherosclerosis. This is a patent application publication establishing a filing date, not a granted patent.

Cancer Therapy Delivery System with Tumbling Container for Suspension Generation

USPTO published patent application US20260096951A1 for a cancer therapy delivery system featuring a tumbler vial for generating therapeutic microsphere suspensions. The system includes a rotation mechanism, fluid inlet and outlet lines configured to twist during rotation, and a cap occluding the vial end. The application was filed on October 9, 2025.

Polymeric Delivery System Patent for Biologics

USPTO published patent application US20260096990A1 for a polymeric delivery system designed to deliver biologic therapeutics to cells. The invention covers polyplexes composed of charged polyesters and biologics, as well as self-assembled particles with block copolymers. The application was filed on December 12, 2025, by inventors Jeremy J. Harris, Scott Radzinski, Brian Ginn, Peter D. Gabriele, and Benjamin Roadarmel.

Biodegradable Microcapsules and Method for Their Preparation

USPTO published patent application US20260096991A1 for biodegradable microcapsules and methods for their preparation. The application relates to microcapsule compositions for drug delivery, classified under A61K. Filing date was September 7, 2023, with nine listed inventors.

Teardrop Effervescent Tablet, Rapid Dissolution, Oral Drug Delivery

USPTO published patent application US20260096993A1 for a teardrop-shaped effervescent tablet designed for rapid dissolution oral drug delivery. The application (No. 18909065) was filed on October 8, 2024 and published April 9, 2026. Inventors Philip Mackenzie and Dan Aziz disclose a tablet with asymmetric geometry and cupped surfaces engineered to accelerate dissolution rates and improve bioavailability of active ingredients.

Solid Dispersions Having Stabilized Emulsion Particles Patent Application

USPTO published patent application US20260096994A1 for solid dispersion compositions containing active pharmaceutical ingredients and dispersion carriers. The application covers methods of dissolving API with carriers, combining with anti-solvent containing surfactant to form emulsions, and removing solvent to achieve predetermined particle size ranges. The application notably includes Compound (1) (zongertinib).

Liquid Formulation of Belumosudil - Kadmon Corporation

USPTO published patent application US20260097036A1 by Kadmon Corporation on April 9, 2026, covering liquid formulations comprising belumosudil, an immunosuppressive agent used in the treatment of subjects. The application was filed on September 20, 2023, under Application No. 19113101, with inventors Olivier Schueller, Galit Regev, Mark Beville, and Nazim Kanji. The published application includes claims directed to liquid pharmaceutical compositions of belumosudil and processes for preparing such formulations.

Kyoto University Pancreatic Endoderm Cell Production Method

USPTO published patent application US20260097083A1 by Kyoto University for a method of producing pancreatic endoderm cells involving culturing the cells in a medium containing a ROCK inhibitor combined with KGF and/or EGF. The application names inventors Kenji Osafune, Yu Hatano, and Azuma Kimura, with CPC classifications spanning A61K 35/39 and C12N 5/0676.

Floating IPN Drug Delivery System for Extended Release

USPTO published patent application US20260096986A1 covering pharmaceutical compositions with a floating interpenetrating polymer network (IPN) system for drug delivery. The compositions contain at least one IPN forming system, at least one drug, and at least one gas generating agent. Upon oral ingestion, the compositions form a floating IPN in situ that provides extended release of the entrapped drug for at least approximately 3 hours. The application was filed on December 12, 2025, under application number 19418060.

BlueRock Therapeutics LP Graft-Related Arrhythmia Treatment Patent Application

The USPTO published patent application US20260097012A1 by BlueRock Therapeutics LP on April 9, 2026, disclosing methods of treating or preventing graft-related arrhythmia in cardiac graft patients by administering combinations of anti-arrhythmic agents including amiodarone, metoprolol, ivabradine, and mexiletine. The application was originally filed on September 27, 2023. This published application makes the invention publicly available for examination and potential licensing or competitive intelligence purposes.

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Maribavir Antiviral Drug Patent, Five Inventors, Filed 2025

Trisubstituted Benzotriazole Derivatives as Dihydroorotate Oxygenase Inhibitors for Cancer Treatment

USPTO published patent application US20260097019A1 disclosing trisubstituted benzotriazole derivatives as dihydroorotate oxygenase inhibitors for treating cancer and inhibiting tumor growth and metastasis. Inventors: Kavitha Nellore and Subramanya Hosahalli. Application filed April 30, 2025.

Therapeutic Use of Aromatase Inhibitors and PARP Inhibitors for Treatment of Malignancies

USPTO published patent application US20260097020A1 covering methods for treating gliomas including glioblastoma using aromatase inhibitors such as letrozole, optionally combined with PARP inhibitors (olaparib, pamiparib, veliparib, or niraparib). The application was filed September 30, 2025 under application number 19345169. Inventors include Pankaj B. Desai, Aniruddha S. Karve, Bhavesh B. Gabani, Sidharth N. Gadgil, and Gary A. Gudelsky.

Unit Oral Dose Compositions of Ibuprofen and Famotidine for Acute Pain and Heartburn Reduction

The USPTO published patent application US20260097023A1 for unit oral dose compositions combining ibuprofen (50-400 mg) and famotidine (3-20 mg) designed to treat acute pain while reducing the severity or risk of heartburn and upset stomach. The formulation specifies that famotidine must dissolve faster than ibuprofen within 45 minutes of administration. The application was filed on December 2, 2025, by inventor Bernard Schachtel.

Stable Amlodipine Oral Liquid Formulations for Hypertension and CAD Treatment

USPTO published patent application US20260097025A1 for stable amlodipine oral liquid formulations filed by inventors Scott Brauer and Gerold L. Mosher. The application covers formulations containing amlodipine for treating hypertension and Coronary Artery Disease (CAD), with CPC classifications in A61K therapeutic preparations. The application was filed on June 17, 2025, under application number 19240194.

Buprenorphine Depot Formulation Controlled-Release Matrix

USPTO published patent application US20260097031A1 for a depot precursor formulation comprising a controlled-release matrix with an oxygen-containing organic solvent and at least 12% by weight buprenorphine or salts thereof. Inventors include Fredrik Tiberg, Ian Harwigsson, and Markus Johnsson. The application covers methods for pain management and opioid maintenance treatment.

Patent: Acetyl Glucosamine Improves Cognition

Patent: Acetyl Glucosamine Improves Cognition

SGLT-2 Inhibitor Pharmaceutical Composition for Diabetes Treatment

The USPTO published patent application US20260097058A1 for a pharmaceutical composition containing SGLT-2 inhibitors for treating diabetes mellitus, impaired glucose tolerance, hyperglycemia, and metabolic disorders. Inventors include Peter Eickelmann, Michael Mark, Leo John Seman, Leo Thomas, Uli Christian Broedl, and Rolf Grempler. The application was filed on December 11, 2025.

Antibacterial Compositions with Avermectin and Melatonin for Demodex Blepharitis Treatment

USPTO published patent application US20260097059A1 covering pharmaceutical compositions for treating Demodex blepharitis. The compositions include avermectin compounds (such as ivermectin derivatives) and melatonin, with optional concentrations under 1 wt %. The application also discloses wipe devices incorporating these treatment compositions. Inventor Rolando Toyos filed the application on January 30, 2025, with publication on April 9, 2026.

ALOX15 Inhibitor Patent Application for Respiratory Disorder Treatment

The USPTO published patent application US20260097102A1 on April 9, 2026, disclosing ALOX15 inhibitors for treating respiratory disorders. Inventors Julie Horowitz and Aris Baras filed the application on October 21, 2025 (Application No. 19364245). The patent covers methods of treating respiratory disorders, identifying at-risk subjects, and detecting ALOX15 variant nucleic acids and polypeptides.

RSV Polyanhydride Nanoparticle Vaccine

The USPTO published patent application US20260096999A9 for a respiratory syncytial virus (RSV) vaccine using polyanhydride nanoparticle delivery technology. The application, filed February 17, 2022 by inventors Steven M. Varga and Kevin L. Legge, claims vaccine compositions including RSV F protein in pre-fusion stabilized form and/or M protein incorporated into biodegradable polyanhydride polymer particles, with optional adjuvant. Patent applications are published to inform the public and allow monitoring of emerging IP positions in the pharmaceutical sector.

Cysteamine for Treatment, Mitigation and Prevention of SARS-CoV-2 Infections

USPTO published patent application US20260097007A1 for cysteamine and derivatives for treating COVID-19 and related viral infections. Inventors are Jess Thoene and Robert Gavin. The application (No. 19415604) was filed December 10, 2025, and published April 9, 2026.

Injectable Composition For Drug Delivery Using Poly Ortho Ester Polymer

USPTO published patent application US20260096985A1 for an injectable drug delivery composition using poly ortho ester (POE) polymer. The composition includes one or more solvents and therapeutic agents, including a basic therapeutic agent, with the POE polymer having a glass transition temperature between approximately −10°C and 110°C per ASTM E1640-18. Inventors are Vijay Gyanani and Jeffrey Haley, with European Application No. 19348865 filed October 3, 2025.

Biocatalytic Composition Patent for Lung Cancer Treatment

Biocatalytic Composition Patent for Lung Cancer Treatment

MegaNano Biotech Files Vaccine Patent Using Dendritic Cells

The USPTO published patent application US20260097104A1 filed by MegaNano Biotech, Inc. on June 12, 2025, covering antigen sensitized exogenous immature dendritic cells for vaccine formulations. The application discloses methods of using dead antigen sensitized exogenous immature dendritic cells to elicit immune responses and methods of disease treatment and prevention.

Avirulent Live Bacterial Vaccines Cured of Plasmids Containing Antimicrobial Resistance Genes

USPTO published patent application US20260097106A1 for avirulent live bacterial vaccines cured of plasmids containing antimicrobial resistance genes. The application, filed September 19, 2023, covers a vaccine comprising live avirulent bacterial strains free of AMR gene-carrying plasmids, a synthetic curing plasmid, and methods for treating bacterial infections while preventing AMR gene transfer.

GlaxoSmithKline Meningococcus Vaccine Patent Application US20260097107A1

The USPTO published patent application US20260097107A1 for GlaxoSmithKline Biologicals SA covering meningococcal vaccines containing multiple alleles or variants of the fHbp protein to broaden coverage. The application was filed on October 29, 2025, and names inventors Alessia BIOLCHI, Brunella BRUNELLI, Marzia Monica GIULIANI, and Vega MASIGNANI.

HPV VLP Bioconjugates Patent, Inventprise, Inc

Inventprise, Inc. has published patent application US20260097109A1 covering immunogenic compositions and vaccines comprising HPV virus-like particle (VLP) bioconjugates. The application includes L2 protein conjugates and methods for treating or preventing HPV infection. Filed October 7, 2025, and published April 9, 2026.

Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy

Cardiac Myosin Inhibitor Aficamten for Hypertrophic Cardiomyopathy

Large-Scale Liposomal Aminoglycoside Manufacturing Method

USPTO published patent application US20260096989A1 by Insmed Incorporated for large-scale manufacturing of liposomal aminoglycoside drug formulations. The method uses a specific lipid-to-drug stream flow rate ratio to achieve high encapsulation efficiency with a lipid-to-drug weight ratio below 1:1.

Helperby Therapeutics Antimicrobial Combination Patent - Three Agents

USPTO published Helperby Therapeutics' patent application for antimicrobial combination therapy comprising three distinct antimicrobial agents. The invention covers combinations including ceftazidime, polymyxins, zidovudine, doxycycline, fosfomycin, levofloxacin, meropenem, rifampicin, and gentamicin for treating bacterial infections. This application was filed September 20, 2023.

Small Molecule NVL2 Inhibitors, Dibenzothiazepinone and Dibenzazepinone Compounds for Cancer Treatment

The USPTO published patent application US20260097047A1 assigned to the Board of Regents, The University of Texas System, covering dibenzothiazepinone and dibenzazepinone-based small molecule inhibitors targeting the ribosome biogenesis factor NVL2 for cancer treatment. The application includes methods for treating cancers, pharmaceutical compositions, and screening methods for candidate therapeutics.

ModernaTX Betacoronavirus mRNA Vaccine Lipid Nanoparticle Patent Application

USPTO published patent application US20260097110A1 by ModernaTX, Inc. for betacoronavirus mRNA vaccines formulated in lipid nanoparticles. The application covers RNA vaccines, combination vaccines, and methods of using the vaccines and compositions. The filing was submitted December 5, 2025, with inventors Giuseppe Ciarametta and Sunny Himansu.

Cannabinoid Analogs Cancer Treatment Patent Application

USPTO published patent application US20260097049A1 by BlackStone Therapeutics LLC covering hexahydrocannabinol (HHC), hexahydrocannabidivarin (H4CBDV), and hexahydrocannabidivarin (H4CBDV) derivatives for cancer treatment and prevention. The application includes pharmaceutical compositions and methods of use for pancreatic and lung cancers.

Ion Pair Liquid Crystal Formulations for Long-Acting Injectables of Poorly Soluble Drugs

USPTO published patent application US20260097044A1 by FORDOZ PHARMA Corp. disclosing ion pair liquid crystal formulations designed to solubilize poorly soluble drugs and enable controlled release via parenteral administration. The application covers ion pairs including Meloxicam-Dodecylamine, Sulfadiazine-Dodecylamine, Methotrexate-Dodecylamine, Levothyroxine-Dodecylamine, Meloxicam-Tridodecylamine, and Meloxicam-Bupivacaine incorporated into liquid crystal vehicles.

Ketamine and NAP patent for ADNP syndrome treatment

Ketamine and NAP patent for ADNP syndrome treatment

N-Acetyl Leucine Treats Niemann-Pick Disease Type C with NPC1 Mutations

The USPTO published patent application US20260097008A1 by inventor Michael Strupp covering methods of treating Niemann-Pick Disease Type C (NPC) or neurological symptoms thereof by administering N-acetyl leucine to subjects carrying NPC1 mutations. The application (No. 19352209) was filed October 7, 2025, and published April 9, 2026.

Adagrasib mTOR Inhibitor Combination Cancer Treatment

USPTO published patent application US20260097038A1 by Mirati Therapeutics covering combination therapies using Adagrasib (KRas G12C inhibitor) with mTOR inhibitors for treating KRas G12C mutant cancers. The application discloses methods of treatment, pharmaceutical compositions, and kits comprising therapeutically effective amounts of both inhibitors.

Methods Of Treating Fabry Patients Having Renal Impairment

USPTO published patent application US20260097027A1 by Amicus Therapeutics Inc. covering methods of treating Fabry disease in patients with renal impairment. The application claims administering migalastat hydrochloride at about 150 mg every other day to patients with HEK assay amenable mutations in α-galactosidase A.